机构:[1]Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,广东省中医院中医药临床研究方法学团队科研大德路总院[2]R&D Information, AstraZeneca, Pudong, Shanghai, China[3]School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai, China
Urinary tract infections (UTIs) are common nosocomial infections. This study evaluated the prevalence, pathogens, antibiotic resistances, clinical outcomes, and hospitalization costs associated with complicated UTIs in southern China, and risk factors delaying patient discharge. We retrospectively reviewed electronic medical records of 4,284 (61.4% women) complicated UTI-related hospitalizations from 2008 to 2013. Average patient age was 61.1 years and median hospital stay was 11 days. Pathogens were isolated from 1,071 urine and 148 blood specimens. Gram-negative bacteria were the most frequent and included Escherichia coli (48.2%), Klebsiella pneumoniae (9.5%), Pseudomonas aeruginosa (4.9%), and Proteus mirabilis (4.6%), while Enterococcus spp. (14.4%) was the most common Gram-positive bacteria causing UTIs. Both E. coli and K. pneumoniae showed high resistance rates (>45%) to wide-spectrum penicillins, cephalosporins, aztreonam, and ciprofloxacin. Resistances to beta-lactamase inhibitor/beta-lactam antibiotic combination were relatively lower. Imipenem, meropenem, and amikacin had the greatest activity against E. coli and K. pneumoniae. Recurrent infection was a risk factor for mortality. Age, sex, previous surgery, diabetes, and renal insufficiency were significant risk factors for delayed discharge (P < 0.01). Response to initial treatment was associated with a lower cost. Initial empiric use of antibiotics least associated with resistance may reduce costs and medical resource usage.
第一作者机构:[1]Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,
共同第一作者:
通讯作者:
通讯机构:[1]Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,[2]R&D Information, AstraZeneca, Pudong, Shanghai, China[*1]R&D Information, AstraZeneca, 199 Liangjing Road, Pudong, Shanghai 201203, China[*2]Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China
推荐引用方式(GB/T 7714):
Li Xiaoyan,Chen Yunqin,Gao Weiguo,et al.A 6-year study of complicated urinary tract infections in southern China: prevalence, antibiotic resistance, clinical and economic outcomes[J].THERAPEUTICS AND CLINICAL RISK MANAGEMENT.2017,13:1479-1487.doi:10.2147/TCRM.S143358.
APA:
Li, Xiaoyan,Chen, Yunqin,Gao, Weiguo,Ye, Hao,Shen, Zhongchao...&Wei, Jia.(2017).A 6-year study of complicated urinary tract infections in southern China: prevalence, antibiotic resistance, clinical and economic outcomes.THERAPEUTICS AND CLINICAL RISK MANAGEMENT,13,
MLA:
Li, Xiaoyan,et al."A 6-year study of complicated urinary tract infections in southern China: prevalence, antibiotic resistance, clinical and economic outcomes".THERAPEUTICS AND CLINICAL RISK MANAGEMENT 13.(2017):1479-1487